Fair is foul.

It sounds lovely to put an end-date on cytotoxic chemo for metastatic KRAS-wild type colorectal cancer. Sadly, just like bevacizumab before it, the EGFR-antagonist panitumumab failed to maintain progression-free survival as monotherapy after 4 months of induction with a 5FU-doublet in a phase 2 trial. | Pietrantonio, JAMA Oncol 2019